Business Context and Reporting Period
Gelteq Limited (GELS) is an Australian public company incorporated in Victoria, listed on the Nasdaq Capital Market. The company develops and commercializes white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and sports nutrition. This Form 20-F covers the fiscal year ended June 30, 2025, compared to the prior fiscal year ended June 30, 2024.
The company operates as a single segment focused on the development and testing of its gel delivery system. It recently completed an Initial Public Offering (IPO) in October 2024, raising approximately USD$5.2 million gross.
Key Financial Metrics
| Metric (AUD$) | Year Ended June 30, 2025 | Year Ended June 30, 2024 |
|---|---|---|
| Revenue | 165,645 | 0 |
| Net Loss | (6,645,453) | (3,546,195) |
| Loss Per Share (Basic & Diluted) | (0.72) | (0.44) |
| Cash and Cash Equivalents | 344,648 | 24,522 |
| Total Assets | 21,475,155 | 20,757,827 |
| Total Liabilities | 5,670,669 | 5,645,530 |
| Working Capital Deficit | (4,125,457) | (3,562,838) |
| Intangible Assets | 19,857,973 | 20,437,958 |
Note: Financial statements are prepared in Australian Dollars (AUD) in accordance with IFRS.
Material Changes vs. Prior Period
- Revenue Recognition: The company recorded revenue of AUD$165,645 in FY2025, compared to nil in FY2024. This revenue was recognized from orders placed in the prior year that were delayed due to customer cash flow issues but were manufactured and delivered in FY2025.
- Net Loss Expansion: Net loss increased by approximately 87% to AUD$6.65 million. This was driven by a significant rise in corporate and administrative expenses (increasing to AUD$6.47 million) and research expenses (increasing to AUD$628,606), partially offset by gains on extinguishment of debt and derivative revaluation.
- Capital Structure: Following the October 2024 IPO, issued capital increased significantly. The company also raised funds through convertible notes and an Equity Line of Credit (ELOC) agreement with Lincoln Park Capital Fund, LLC.
- Debt Profile: Borrowings increased, with a reclassification of shareholder loans from non-current to current liabilities due to maturity dates. Convertible notes payable increased to AUD$2.04 million.
Guidance, Outlook, and Risks
Outlook and Strategy: Management projects revenue growth of approximately 213% annually over the next four years, aiming for profitability by FY2028. Strategic priorities for the 2026 fiscal year include pursuing the FDA 505(b)(2) pathway for a prescription drug, conducting clinical trials, and expanding sales in the nutraceutical and sports verticals. The company plans to onboard additional sales managers to meet revenue targets.
Going Concern: The filing explicitly states there is substantial doubt about the company's ability to continue as a going concern. This is due to a history of operating losses, a working capital deficit, and recurring losses. The financial statements are prepared on a going concern basis, contingent on the company's ability to raise additional capital, secure regulatory approvals, and generate revenue.
Key Risks:
- Capital Requirements: The company requires substantial additional financing to achieve its goals. Failure to obtain capital could force delays in product development or commercialization.
- Market Acceptance: Demand for the company's new class of gel products is unknown, and operating results may fluctuate significantly.
- Regulatory Approval: While some products are food-grade, pharmaceutical products require FDA approval, which is lengthy, expensive, and uncertain.
- Supply Chain: Reliance on third-party manufacturers (including in China) and limited raw material suppliers creates supply chain risks.
- Geopolitical Factors: Global conflicts and trade tensions (specifically US-China tariffs) could impact manufacturing costs and supply chains.
Investor Verification Checklist
- Going Concern Status: Verify the company's progress in securing the additional financing required to meet its working capital deficit and operational needs.
- Revenue Sustainability: Confirm whether the FY2025 revenue was a one-time recognition of backlogged orders or indicative of a recurring sales pipeline.
- Regulatory Milestones: Monitor the status of the FDA 505(b)(2) application and the suitability petition for the new animal drug, as these are critical for future high-margin revenue.
- Debt Maturities: Review the terms of the shareholder loans and convertible notes maturing in December 2025 and July 2026 to assess refinancing or conversion risks.
- Intangible Asset Valuation: Assess the assumptions used in the impairment testing of intangible assets (which comprise ~92% of total assets), specifically the projected 213% annual revenue growth rate.